Improved quality of life is the way to longer life
Mené dans 24 pays, cet essai de phase III analyse la qualité de vie de patients atteints d'un carcinome à cellules rénales de stade avancé en fonction du traitement reçu, nivolumab ou évérolimus (411 patients inclus entre 2012 et 2014)
In The Lancet Oncology, David Cella and colleagues1 report the quality-of-life results from the previously published Checkmate 025 trial.2 The original study, which included patients with advanced renal cell carcinoma previously treated with antiangiogenic therapies, showed that nivolumab was superior to everolimus in terms of overall survival (the primary endpoint of the study), proportion of patients achieving an objective response, tolerability, and quality of life. No differences in progression-free survival were detected.
The Lancet Oncology , éditorial, 2015